Table 1 Clinical information on Patients and corresponding NSG Xenografts
| Â | Patient and disease characteristics at initial diagnosis | Disease characteristics of clinical samples (Dx and R) xenografted in NSG mice | Xenograft characteristics | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Patient ID | Diagnosis | Sex | Age (years) | Cytogenetics | Risk group | Sample Time-Point | Time to Disease Progression (months) | Risk Group | Cytogenetics* | MNC Source | Patient Blast Content (%) | Injected viable MNCs | Xenograft ID | Time to Progression in PDX (days) | PDX Tumor Content (%) |
1 | B-01-Dx | B-ALL | F | 11 | Constitutional trisomy 21 Trisomy X | HR | Dx | NA | - | Constitutional trisomy 21 Trisomy X | BM | 94 | 1M | B-01-Dx-PDX | 146 | 92 |
2 | B-02-Dx | B-ALL | F | 3 | Variant t(12;21) with ETV6/RUNX1 fusion Multiple chromosomal rearrangments [t(X;2), t(4;12;21), t(5;7), t(10;11), t(16;19)] | HR | Dx | NA | - | Variant t(12;21) with ETV6/RUNX1 fusion Multiple chromosomal rearrangments [t(X;2), t(4;12;21), t(5;7), t(10;11), t(16;19)] | BM | 97 | 1M | B-02-Dx-PDXa | 146 | 99 |
| Â | Â | 1M | B-02-Dx-PDXb | 130 | 98 | |||||||||||
3 | B-03-Dx | B-ALL | F | 2 | Hemizygous deletion of p16 (CDKN2A) locus, del(9) | AR | Dx | NA | - | Hemizygous deletion of p16 (CDKN2A) locus, del(9) | BM | 93 | 1M | B-03-Dx-PDXa | 87 | ND |
| Â | Â | 1M | B-03-Dx-PDXb | 82 | 94 | |||||||||||
4 | B-04-Dx | B-ALL | F | 15 | Cryptic t(12;21) with ETV6/RUNX1 fusion, Monosomy X, Complex abnormal karyotype, [(t,4;12)] | HR | Dx | NA | - | Cryptic t(12;21) with ETV6/RUNX1 fusion, Monosomy X, Complex abnormal karyotype, [(t,4;12)] | BM | 95 | 1M | B-04-Dx-PDX | 361 | 95 |
5 | B-05-R1 | B-ALL post B-cell Lymphoma | F | 3 | ND | - | R1 | 17 | VHR | Normal: 46,XX | BM | 68 | 1M | B-05-R1-PDX | 255 | 98 |
6 | B-06-R2 | B-ALL | M | 13 | ND | - | R2 | 31 | HR | Homozygous deletion of CDKN2A locus Complex karyotype [t8;9), t(13;17)] | BM | 96 | 1M | B-06-R2-PDXa | 246 | 96 |
| Â | 1M | B-06-R2-PDXb | 240 | 98 | ||||||||||||
7 | B-06-R3 | 15 | ND | - | R3 | 15 | VHR | Homozygous deletion of CDKN2A locus Highly abnormal karyotype, [t(8;9), t(13;17)] | BM | 90 | 1M | B-06-R3-PDXa | 158 | 92 | ||
| Â | 1M | B-06-R3-PDXb | ND | ND | ||||||||||||
8 | B-07-R3 | B-ALL | M | 15 | NORMAL: 46,XY | - | R3 | 12 | VHR | Homozygous deletion of CDKN2A locus | Blood | Numerous | 1.6M | B-07-R3-PDXa | 46 | 94 |
| Â | 1.6M | B-07-R3-PDXb | 46 | 92 | ||||||||||||
9 | B-08-R2 | B-ALL | F | 17 | Trisomy X | - | R2 | 24 | VHR | Trisomy X RUNX1 amplification Complex karyotype, [t(2;12), t(3;8), t(4;17;14), t(12;15), t(12;16)] | BM | 94 | 1M | B-08-R2-PDX | 137 | ND |
10 | T-01-Dx | T-ALL | M | 5 | Cryptic heterozygous deletion of CDKN2A | HR | Dx | NA | Â | Cryptic heterozygous deletion of CDKN2A | BM | 81 | 1M | T-01-Dx-PDX | 69 | 92 |
11 | T-01-R1 | T-ALL | 5 | - | R1 | 60 | HR | Cryptic heterozygous deletion of CDKN2A | BM | 2 | 1M | T-01-R1-PDXa | 61 | 98 | ||
| Â | (Isolated CNS relapse with 2% bone marrow infiltration) | 1M | T-01-R1-PDXb | 55 | ND | |||||||||||
12 | T-02-Dx | T-ALL | M | 13 | Monosomy 14 Interstitial deletion of chr. 6(q) | HR | Dx | NA | - | Monosomy 14 Interstitial deletion of chr. 6(q) | BM | 90 | 0.7M | T-02-Dx-PDX | 240 | 99 |
13 | T-03-Dx | metastatic T-cell lymphoblastic lymphoma | F | 10 | Hyperdiploidy (+6, +8, +10, +11, +13, +19, +19) | ND | Dx | NA | - | Hyperdiploidy (+6, +8, +10, +11, +13, +19, +19) | BM | 8 | 1M | T-03-Dx-PDX | 208 | 94 |
14 | NL-01 | GATA2 mutation | M | 6 | Normal: 46, XY | NA | Non-leukemic | - | NA | - | BM | 0 | NA | NA | NA | NA |
15 | NL-02 | Thrombocytopenia & macrocytosis | F | 17 | Normal: 46, XX | NA | Non-leukemic | - | NA | - | BM | 0 | NA | NA | NA | NA |